anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND/OBJECTIVES: Hyperuricemia (HUA) is a common metabolic disease caused by purine metabolic disorders in the body. Portulaca oleracea L. (PO) is an edible wild vegetable.
METHODS: In this study, the regulatory effect of PO on HUA and its potential mechanism were initially elucidated through network pharmacology and experimental validation.
RESULTS: The results showed that PO from Sichuan province was superior to the plant collected from other habitats in inhibiting xanthine oxidase (XOD) activity. Berberine and stachydrine were isolated and identified from PO for the first time by UPLC-Q-Exactive Orbitrap MS. The potential molecular targets and related signaling pathways were predicted by network pharmacology and molecular docking techniques. Molecular docking showed that berberine had strong docking activity with XOD, and the results of in vitro experiments verified this prediction. Through experimental analysis of HUA mice, we found that PO can reduce the production of uric acid (UA) in the organism by inhibiting XOD activity. On the other hand, PO can reduce the body 's reabsorption of urate and aid in its excretion out of the body by inhibiting the urate transporter proteins (GLUT9, URAT1) and promoting the high expression of urate excretory protein (ABCG2). The results of H/E staining showed that, compared with the positive drug (allopurinol and benzbromarone) group, there was no obvious renal injury in the middle- and high-dose groups of PO extract.
CONCLUSIONS: In summary, our findings reveal the potential of wild plant PO as a functional food for the treatment of hyperuricemia.
This is a prospective, observational, single-center study. The study center will be the Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England. The aim of this study is to collect clinical, procedural, and follow-up data in order to evaluate the efficacy and safety of the Hydra THV series (Vascular Innovations Co. Ltd., Nonthaburi, Thailand). Additionally, the study will conduct the remote ambulatory cardiac monitoring (rACM) using the Checkpoint Cardio System, consisting of 72 hours of continuous electrocardiogram (ECG) monitoring, will be evaluated post hospital discharge and coronary access will be evaluated immediately post-TAVI by attempting to selectively engage both the right and left coronary arteries through standardized angiographic views. The operator will attempt to achieve commissural alignment for the Hydra THV series using the commissural alignment technique as specified in section 3.4 of this protocol, contingent upon the patient's condition during the procedure. Following discharge, clinical follow-ups are scheduled at 1-month (±7 days), and 1-year (±30 days).
FIELD: biotechnology. SUBSTANCE: method involves the use of 25-30% suspension of rabbit liver dead after viral hemorrhagic disease prepared on the buffered solution, pH 7.2, Virus is extracted twice for 20-48 hr at 6 ±  2 C, at periodic stirring and filtration through the sterile cotton-gauze filter. Inactivation of viral raw is carried out at 60 C for 5 hr. Material is stabilized by addition of 5% lactose and 1% gelatin at the ratio 1:1 and stabilizing agent followed by lyophilization. EFFECT: improved method of vaccine preparing. 4 tbl
SEROQUEL XR is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of SEROQUEL XR in manic or mixed episodes of bipolar I disorder was established in one 3-week trial in adults with manic or mixed episodes associated with bipolar I disorder. Efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with bipolar I disorder as well as one 3-week monotherapy trial in children and adolescents (10 – 17 years) with manic episodes associated with bipolar I disorder treated with SEROQUEL [see Clinical Studies (14.2)].

SEROQUEL XR is indicated for the acute treatment of depressive episodes associated with bipolar disorder. The efficacy of SEROQUEL XR was established in one 8-week trial in adults with bipolar I or II disorder and supported by two 8-week trials in adults with bipolar I or II disorder treated with SEROQUEL [see Clinical Studies (14.2)].

SEROQUEL XR is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was extrapolated from two maintenance trials in adults with bipolar I disorder treated with SEROQUEL. The effectiveness of monotherapy for the maintenance treatment of bipolar I disorder has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.2)].
PURPOSE:To detoxify capsule by forming microcapsule by phase separation with addition of aq. liquid, etc., using polyvinylacetal diethylaminoacetate, methyl methacrylate, etc., as wall material. CONSTITUTION:A solution of the wall material contg. one or more kinds of polyvinylacetal diethylaminoacetate, dimethylaminoethyl methacrylate-methyl methacrylate copolymer, methyl methacrylate-methacrylic acid copolymer, hydroxypropylmethylcellulose acetate phthalate, etc., is prepared. The microcapsule is produced by phase separation adding aq. liquid, or acid or base, etc., to the soln. of wall material. Water or aq. soln. of polymer soluble in water or water and ethanol is pref. as the aq. liquid above-mentioned.
PURPOSE: The HUNT Lung Cancer Model (HUNT LCM) predicts individualized 6-year lung cancer (LC) risk among individuals who ever smoked cigarettes with high precision based on eight clinical variables. Can the performance be improved by adding genetic information?
METHODS: A polygenic model was developed in the prospective Norwegian HUNT2 study with clinical and genotype data of individuals who ever smoked cigarettes (n = 30749, median follow up 15.26 years) where 160 LC were diagnosed within six years. It included the variables of the original HUNT LCM plus 22 single nucleotide polymorphisms (SNPs) highly associated with LC. External validation was performed in the prospective Norwegian Tromsø Study (n = 2663).
RESULTS: The novel HUNT Lung-SNP model significantly improved risk ranking of individuals over the HUNT LCM in both HUNT2 (p < 0.001) and Tromsø (p < 0.05) cohorts. Furthermore, detection rate (number of participants selected to detect one LC case) was significantly better for the HUNT Lung-SNP vs. HUNT LCM in both cohorts (42 vs. 48, p = 0.003 and 11 vs. 14, p = 0.025, respectively) as well as versus the NLST, NELSON and 2021 USPSTF criteria. The area under the receiver operating characteristic curve (AUC) was higher for the HUNT Lung-SNP in both cohorts, but significant only in HUNT2 (AUC 0.875 vs. 0.844, p < 0.001). However, the integrated discrimination improvement index (IDI) indicates a significant improvement of LC risk stratification by the HUNT Lung-SNP in both cohorts (IDI 0.019, p < 0.001 (HUNT2) and 0.013, p < 0.001 (Tromsø)).
CONCLUSION: The HUNT Lung-SNP model could have a clinical impact on LC screening and has the potential to replace the HUNT LCM as well as the NLST, NELSON and 2021 USPSTF criteria in a screening setting. However, the model should be further validated in other populations and evaluated in a prospective trial setting.
FIELD: veterinary science, poultry farming. SUBSTANCE: invention relates to vaccine preparations against infectious diseases, namely, against virus causing "Egg yield decrease syndrome-76" and methods of vaccination. Invention proposes the vaccine preparation against viruses causing "Egg yield decrease syndrome-76" where inactivated virus is enclosed into liposomal vesicle covered by envelope that consists of a mixture of sugars and water-soluble polymers taken in the ratio = (5-15):1. Vaccination is carried out by administration of vaccine in poultry body (age is 110-140 days) by oral watering route in the dose 512-2048 hemagglutination units/05. Preparation is harmless for poultry and shows expressed antigenic and immunogenic activity. EFFECT: decreased cost, increased rate of vaccination as compared with conventional method of disease prophylaxis. 6 cl, 2 tbl, 2 ex
An RF signal is provided by a base such as a smart phone. A remote is engaged with a medication container. The remote includes an RFPM, RF signal receiver, LO signal generator, and IF signal emitter. An energizer on the remote provides power only as medication is dispensed. While energized, the RFPM modulates the RF signal with an LO signal to produce an IF signal. The existence of the IF signal (characteristic of the RFPM, RF signal, and LO signal) thus indicates medication has been dispensed. The IF signal is detected in the base, and registered (recorded, displayed, communicated, etc.) as an indication that medication has been dispensed. The remote may be configured as a label applied to or a sleeve engaged with an otherwise “non-smart” container. This provides authenticated data regarding medication adherence, transparent to the user and requiring no additional user actions to register the data.
Selegiline hydrochloride is a levorotatory acetylenic derivative of phenethylamine. It is commonly referred to in the clinical and pharmacological literature as 1-deprenyl.

The chemical name is: (R)-(-)- N,2-dimethyl- N-2-propynylphenethylamine hydrochloride. It is a white to near white crystalline powder, freely soluble in water, chloroform, and methanol, and has a molecular weight of 223.74. The molecular formula is C 13H 17N•HCl. The structural formula is as follows: 

Each tablet, for oral administration, contains 5 mg selegiline hydrochloride. Inactive ingredients are corn starch, lactose monohydrate, microcrystalline cellulose, povidone, and stearic acid.
Acute myocardial infarction (AMI) is one of the leading causes of death worldwide and treatment costs pose a major burden on the global health care system. Despite the variety of treatment options, individual recovery can be still poor and the mortality rate, especially in the first few years after the event, remains high. Therefore, intense research is currently focused on identifying novel target molecules to improve the outcome following AMI. One of the potentially interesting targets is the serotonergic system (5-HT system), not at least because of its connection to mental disorders. It is known that patients suffering from AMI have an increased risk of developing depression and vice versa. This implicates that the 5-HT system can be affected in response to AMI and might thus represent a target structure for patients' treatment. This review aims to highlight the importance of the 5-HT system after AMI by describing the role of individual serotonin receptors (5-HTR) in the regulation of physiological and pathophysiological responses. It particularly focuses on the signaling pathways of the serotonin receptors 1, 2, 4, and 7, which are expressed in the cardiovascular system, during disease onset, and the following remodeling process. This overview also emphasizes the importance of the 5-HT system in AMI etiology and highlights 5-HTRs as potential treatment targets.
FIELD: medicine. SUBSTANCE: homogenized milt of salmon and sturgeon fishes were subjected for autolysis at pH 4.5-5.0 with lysosomal enzymes. Autolysate is separated for liquid fraction and precipitate which is subjected for enzymatic hydrolysis. Hydrolysate of salmon fishes milt has value bioactive products, such as amino acids, deoxynucleosides, oligonucleotides of different size. EFFECT: improved method of hydrolysate preparing. 5 cl, 2 tbl
NF 1 patients with scoliosis can present as either non dystrophic or dystrophic scoliosis. Non dystrophic scoliosis behaves and evolves similarly to that of AIS patients. Therefore, we hypothesize that Neurofibromatosis type 1 patients with non-dystrophic scoliosis have a similar curve progression risk profile markers as patients with Adolescent Idiopathic Scoliosis. Dystrophic scoliosis patients will not have the same curve progression risk profile as AIS. The long range goal of this study is to possibly develop a genetic test in NF1 patients with scoliosis that is predictive of dystrophic or non-dystrophic type. The short term goal for the study is to see if the non-dystrophic curves have the same single-nucleotide polymorphisms (SNPs') as in AIS and if these SNPs are prognostic.

One of the goals of this study is to develop and validate a grading scheme to classify dystrophic changes in patients with NF 1 scoliosis. Radiographic characteristics of dystrophic deformity described by Crawford and Durrani et. al. will distinguish dystrophic scoliosis from non-dystrophic scoliosis. In addition, we will be performing genetic testing on patients with NF 1 who have had clinical treatment for scoliosis. Although the NF1 gene has been identified no specific genetic markers have been identified in NF1 patients with scoliosis. Genetic evaluation on a known group of NF1 patients with scoliosis will allow us to gain insight as to which phenotypes of NF1 patients would possibly develop spine deformities.
PROBLEM TO BE SOLVED: To obtain a target growth hormone secretion-regulating substance or growth hormone secretion regulator by developing a superior screening method for the growth hormone secretion-regulating substance such as a growth hormone secretagogue or the like, and make use of the regulating substance or regulator for preventing and improving diseases by reason of growth hormone acathexia and/or developing remedies against the diseases. SOLUTION: A substance to be tested is administered to mammals each having little sensitivity to stress or having the sensitivity to stress reduced. Blood is collected at predetermined intervals from the mammals before and after the administration. A concentration of the growth hormone included in the blood is measured. A pulse secretion quantity and a pulse secretion pattern in a predetermined time before and after the administration of the substance to be tested are obtained preferably by an AUC. The obtained pulse secretion quantities and/or the pulse secretion patterns before and after the administration of the substance to be tested are compared with each other, thereby judging whether or not a substantial change is present therein. The growth hormone secretion-regulating substance can be screened or produced in this manner.
This was a four-week study designed to investigate GI mucosal lesions by SBCE in kidney transplant recipients who were using MMF, and to examine the changes in clinical symptoms and intestinal mucosa lesions 30 days after switching over from MMF to EC-MPS. The patient was switched from MMF to EC-MPS (Myfortic) on the equimola basis.
A composition for the diagnosis of diseases relating to amyloid which contains either a compound represented by the general formula (I): [wherein X represents O, etc.; R1, R3, R4, R5, R6, R8, and R9 each represents hydrogen, etc.; R2 represents halogeno, etc.; and R7 represents dimethylamino, etc.] or a compound obtained by labeling that compound with a radionuclide or contains a pharmaceutically acceptable salt of any of these compounds. The compound represented by the general formula (I) has high bonding specificity for amyloid beta-protein, is apt to highly pass through the blood-brain barrier, and has the property of rapidly disappearing from the areas excluding senile plaques in the brain. ® KIPO & WIPO 2009
Longitudinal, multi-center, and non-interventional registry. Patients will be identified as eligible for pulmonary artery pressure sensor implant by a heart failure cardiologist from the heart failure clinic. They will consent for device implant and procedure (right heart catheterization) per standard of care. Patients may also consent to the registry participation, which is optional. They will be informed that the registry intends to gather data and that they may be approached in the future for additional research based on their data and clinical situation. Additionally, patients who underwent pulmonary artery pressure sensor implantation from January 1, 2019, will be identified and consent will be obtained for registry participation, which is optional.
HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
The invention discloses a Chinese fir wood and gypsum formula for eliminating dampness and expelling toxin, which comprises Chinese fir wood. The Chinese fir wood comprises Chinese fir wood plates, Chinese fir wood nodes, Chinese fir wood roots and Chinese fir wood barks; and the Chinese fir wood is compatible with gypsum, the mixture is decocted with water, dregs are removed and the decoction is taken. If the Chinese fir wood is the Chinese fir wood plates or Chinese fir wood barks, the Chinese fir wood plates or Chinese fir wood barks are compatible with the gypsum, the mixture is decocted with water, dregs are removed and the decoction is taken; and the mass ratio of the Chinese fir wood plates or Chinese fir wood barks to the gypsum to the water is 5:2:75. If the Chinese fir wood is the Chinese fir wood nodes, the Chinese fir wood nodes are compatible with the gypsum, the mixture is decocted with water, dregs are removed and the decoction is taken; and the mass ratio of the Chinese fir wood nodes to the gypsum to the water is 2:1:35; if the Chinese fir wood is the Chinese fir wood roots, the Chinese fir wood roots are compatible with the gypsum, the mixture is decocted with water, dregs are removed and the decoction is taken; and the mass ratio of the Chinese fir wood roots to the gypsum to the water is 6:2:85. The formula is scientific and reasonable, and simple and feasible, can treat dermatophytosis, eczema and skin itching sores and has obvious effects of eliminating dampness and expelling toxin. The formula can be orally taken or externally used, and particularly can be blended into beverages with various tastes.
FIELD: medicine, biotechnology. SUBSTANCE: invention relates to methods of preparing extracts of shark cartilage showing antiangiogenic, antitumor-proliferating, anti-inflammatory and anticollagenolytic activities. Method of preparing involves stages of preparing cartilage homogenate in an aqueous solution, centrifugation of homogenate and further fractionation up to preparing the complete extract containing molecules of molecular mass up to 500 kDa. Additional fractionation of extract results to preliminary characterization of its active components. Complete liquid extract can be used for treatment of patients with diseases or states including one or more etilogical components and involving tumor proliferation, angiogenesis, inflammations and collagenolysis. This extract does not show any harmful effect on normal body functions. EFFECT: enhanced therapeutic effectiveness of shark cartilage extract, simplified method of preparing. 72 cl, 19 dwg
Buprenorphine hydrochloride is a narcotic under the Controlled Substances Act due to its chemical derivation from thebaine. Chemically, it is 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-6,14-ethenomorphinan-7-methanol, hydrochloride [5α, 7α(S)]. Buprenorphine hydrochloride is a white powder, weakly acidic and with limited solubility in water. Buprenorphine hydrochloride injection is a clear, sterile, injectable agonist-antagonist analgesic intended for intravenous or intramuscular administration. Each mL of buprenorphine hydrochloride injection contains 0.324 mg buprenorphine hydrochloride (equivalent to 0.3 mg buprenorphine), 50 mg anhydrous dextrose, water for injection, and HCl to adjust pH to 3.5 to 5.5. Buprenorphine hydrochloride has the molecular formula, C29H41NO4·HCl and the molecular weight of 504.09. It has the following structural formula:
Oesophagogastric adenocarcinomas (OAC) are poor prognosis, obesity-associated cancers which may benefit from natural killer (NK) cell-based immunotherapies. Cellular immunotherapies encounter two key challenges to their success in OAC, namely recruitment to extratumoural tissues such as the omentum at the expense of the tumour and an immunosuppressive tumour microenvironment (TME) which can hamper NK cell function. Herein, we examined approaches to overcome the detrimental impact of obesity on NK cells and NK cell-based immunotherapies. We have demonstrated that NK cells migrate preferentially to the chemotactic signals of OAC patient-derived omentum over tumour in an ex vivo model of immune cell migration. We have identified CX3CR1 modulation and/or tumour chemokine profile remodelling as approaches to skew NK cell migration towards tumour. We also report targetable immunosuppressive facets of the obese OAC TME which dampen NK cell function, in particular cytotoxic capabilities. These data provide insights into approaches to therapeutically overcome key challenges presented by obesity and will inform superior design of NK cell-based immunotherapies for OAC.
BACKGROUND: Despite the high rates of cholecystectomy in Australia, there is minimal literature regarding the outcomes of cholecystectomy in rural Central Australia within the Northern Territory. This study aims to better characterize the outcomes for patients undergoing cholecystectomy in Central Australia and review clinical and patient characteristics, which may affect outcomes.
METHOD: A retrospective case-control study was performed using data obtained from medical records for all patients undergoing cholecystectomy at Alice Springs Hospital in the Northern Territory from January 2018 until December 2022. Patient characteristics were gathered, and key outcomes examined included: inpatient mortality and 30-day mortality, bile duct injury, bile leak, return to theatre, conversion to open, duration of procedure, length of stay, and up-transfer to a tertiary referral centre.
RESULTS: A total of 466 patients were included in this study. Majority of the patients were female and there was a large portion of Indigenous Australians (56%). There were no inpatient mortalities, or 30-day mortalities recorded. There were two bile leaks and/or bile duct injuries (0.4%) and two unplanned returned to theatres (0.4%). Indigenous Australians were more likely to require an emergency operation and had a longer median length of stay (P < 0.001).
CONCLUSION: Cholecystectomy can be performed safely and to a high standard in Central Australia. Surgeons in Central Australia must appreciate the nuances in the management of patients who come from a significantly different socioeconomic background, with complex medical conditions when compared to metropolitan centres.